ComboMATCH trials will use Exact Sciences' (EXAS) new OncoExTra™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials ...

Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday ...

Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical ...

Exact Sciences’ multi-cancer early detection (MCED) blood test has achieved 50.9% sensitivity at 98.5% specificity across 21 cancer types, the company said Monday at the American Association for ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...